Akeso Inc.
Industry
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
- Pharmaceuticals
Other Names/Subsidiaries
- Akesobio
- Akesobio Australia Pty Ltd
- Akeso Biopharma, Inc.
- Kangfang Biotechnology
Latest on Akeso Inc.
As China’s immuno-oncology market adapts to the ever-growing ranks of homegrown PD-1/L1-targeting agents, SinoCellTech has received approval for what will be the 17th product in the sector - but the f
Pfizer/Arvinas’s VERITAC-2 Study Of Vepdegestrant In 2025, the first Phase III clinical readout for a PROTAC degrader is expected in an important milestone for the targeted protein degradation (TPD)
A healthy total of 61 novel drugs were approved in the US in the course of 2024, but just a handful of these look certain to generate the multi-billion dollar sales that big pharma increasingly needs.
2024 got off to a good start for Vertex with positive Phase III studies of its novel pain therapy, suzetrigine (then known as VX-548), reported in January. The non-opioid, oral selective inhibitor of